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Introduction. In Permanent Prostate Implants (PPI)with radioactive seeds a post-plan is required after completion of the implant. To
calculate thepost-plan it is required to register two imaging studies and the automatic search for theposition of the seeds. Purpose.
To improve process efﬁciency in the post-plan after a PPI (exact location of the implanted seeds, reliability of the registration and
decrease in time).
Material and method. Certain variables used in the planning system (PS) for image registration and automatic search of seeds
were determined. The PS used was SPOT PRO v3.0 by Nucletron. The method employed to make image registration was point
matching. Quantitative result shown by the Root Mean Square (RMS). Image registration was performed in ten patients by two
Radiation Oncologists (RO) One of the RO performed the registration using both three and four points. Different threshold values
were introduced in Hounsﬁeld Units (HU) for seeds and bone with the maximum and minimum area of the image of a seed. The
coincidence between the number of seeds implanted and those detected by the PS were analyzed.
Results. The average measure of intraclass correlation coefﬁcient (ICC) using an ANOVA model two-way random with absolute
agreement is 0.857 (95% CI: 0.427–0.965) to RMS of record measured by two Radiation Oncologists and 0.740 (95% CI: 0.000–0.938)
to RMS of record measured using three and four points for matching.
Conclusion. The reliability of the image registration allows the use of only three points for matching. The result is independent
of the doctor who performs it. The best results to automatically search for the seed by the PS were obtained with the values of
1000HU to seed threshold, 150HU to bone threshold, 0.5mm2 to minimum spot area and 50mm2 to maximum spot area.
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Introduction. GEC-ESTRO recommendations for IGRT in brachytherapy, the incorporation of MRI in the planning and new MRI-
compatible applicators have improved our treatments. But, in big tumours, intrauterine applicators do not seem enough in
order to reach a good coverage. Interstitial CT-MRI Utrecht (Nucletron®) applicator with plastic needles lets improve HR-CTV and
IR-CTV coverage sparing organs at risk.
Objective. To review clinical outcomes, toxicity and dosimetry in patients with cervix tumours using interstitial CT-MRI Utrecht
applicator.
Material and methods. Retrospective review of the records of 52 cervical cancer patients treated in our institution from February
10 to October 12. To be included in the study, the treatment had to fulﬁll the criteria: (1) include a previous treatment of at least
45Gy of EBRT to the pelvis concomitant with cisplatin; (2) the BT boost consisted in insertion of a interstitial Utrecht applicator
under spinal anesthesia and individualized MRI planning. Each treatment was composed of 2 applications (7 days apart), with 2
separated fractions of ∼7Gy (in 24h). Toxicity scores were deﬁned by CTCAE v3.0.
Results. 41/52 patients have available data. Inmost of them6needleswere inserted. The ﬁnal average biologically equivalent doses
(EQD2) were: D90 HR-CTV=86.4Gy; D90 IR-CTV=66.3Gy; 2 cm3 maximum dose for bladder was 74.4Gy and 63.4Gy and 58.2Gy
respectively for rectum and sigmoid. 4 patients presented haemorrhage when application was removed. Median follow-up was
19 months (3–35). GU and GI G≥3 toxicities occurred in 2 (4.8%) and 1 (2.4%) patients respectively. 6 (14.6%) patients developed
systemic failure, but only 3 (7.3%) patients experienced local relapse, associated with large tumours with poor response to EBRT.
Cancer speciﬁc survival was 92.6%.
Conclusions. Our results suggest that interstitial IGBT as recommended by the GEC-ESTRO, is safe, in terms of local control and
morbidity. These clinical and dosimetric results compare favourably with the traditional technique.
http://dx.doi.org/10.1016/j.rpor.2013.03.044
Perioperative interstitial high-dose-rate brachytherapy in tongue carcinoma
L. Corrales, V. Carrizo, J. Guinot, M. Tortajada, M. Santos, A. Mut, L. Arribas
Instituto Valenciano de Oncología, Oncología Radioterápica, Spain
Abstract purpose. To evaluate the results of perioperative interstitial high-rate-dose brachytherapy (PIHB) in patients with tongue
carcinoma.
Materials and methods. Between June 2003 and January 2013, 34 patients with tongue carcinoma were treated with partial glos-
sectomy and PIHB. In 21 cervical lymph node dissection was performed as well. Median age was 62 (24–93). Eleven patients were
stage pT1, nineteen pT2 and four pT3, with lymph node involvement in 12 of them. EBRT 50–60Gy was administrated to 40% of
the patients, and 4 received chemotherapy. The brachytherapy technique used plastic tubes, implanted in the surgical bed just
